Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fespixon (Oneness Biotech Co., Ltd., 0439aa)
- Development stage
- Unknown
- Lead developer
- Oneness Biotech
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
ON101 (fespixon) is a first-in-class topical botanical drug developed by Oneness Biotech for the treatment of chronic wounds, primarily diabetic foot ulcers (DFU). It is composed of specific extracts from *Plectranthus amboinicus* (Lour.) Spreng. and *Centella asiatica* (L.) Urb. The cream works by modulating the wound microenvironment, specifically by promoting the polarization of macrophages from a pro-inflammatory M1 phenotype to a pro-healing M2 phenotype. This shift reduces the levels of inflammatory cytokines such as TNF-α and IL-6 while enhancing collagen deposition and angiogenesis, facilitating the closure of hard-to-heal ulcers. It has received regulatory approval in several Asian markets, including Taiwan, Singapore, and Malaysia, and is undergoing global Phase 3 clinical trials to support broader international registration.
- Brand names
- Fespixon
- Other names
- PA-F4 + S1Plectranthus amboinicus extract + Centella asiatica extract
Beyond the preview
Go deeper on fespixon (Oneness Biotech Co., Ltd., 0439aa).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fespixon (Oneness Biotech Co., Ltd., 0439aa).